SUNIL PATEL - Corporate Board Profile

LIGAND PHARMACEUTICALS INC

Filing Date	Source Excerpt
2014-04-21	Sunil Patel(A) Director 2010 42 ... The audit committee currently consists of Messrs. Knott and Patel and Dr. Sabba (chair). ... Sunil Patel(5) 55,000 94,478 149,647 — 299,125 ... (5) As of December 31, 2013, Mr. Patel held options to purchase 27,005 shares of our common stock and 19,873 unvested shares of restricted stock. During 2013, Mr. Patel received 2,925 restricted stock units with a grant date fair value of $94,478 and 7,335 stock options with a grant date fair value of $149,647. Mr. Patel elected to receive 1,393 shares of fully vested stock in lieu of $45,000 of his 2013 cash retainer for his services as a non-employee director.
2015-03-13	Sunil Patel(A) - Director, Age 43, Member of the audit committee (A). Compensation: $272,659 in 2014.
2016-04-12	Sunil Patel(A) Director 44 2010 (A) Member of the audit committee ... Compensation of Directors ... Sunil Patel(5) As of December 31, 2015, Mr. Patel held options to purchase 33,071shares of our common stock and 925 restricted stock units. During 2015, Mr. Patel received 925 restricted stock units with a grant date fair value of $83,019 and 2,754 stock options with a grant date fair value of $139,946. ... Cash Fees $55,064 Stock Awards $83,019 Option Awards $139,946 Total $278,029
2017-04-14	Sunil Patel(A) Director 2010 45 ... The audit committee currently consists of Messrs. Davis and Patel and Dr. Sabba (chair). ... Sunil Patel 55,144 74,205 140,557 269,906 ... During 2016, Mr. Patel received 622 restricted stock units with a grant date fair value of $74,205 and 2,329 stock options with a grant date fair value of $140,557.
2018-04-30	Sunil Patel Director 2010 46; Member of the audit committee; 2017 compensation total $266,790.
2019-04-24	Sunil Patel (A) 47 2010 Former Executive Vice President and Chief Financial Officer for OncoMed Pharmaceuticals ... Mr. Patel received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. Total: $338,365.
2020-04-24	Sunil Patel (A) 48 2010 Former Executive Vice President and Chief Financial Officer for OncoMed Pharmaceuticals ... Mr. Patel executive and corporate development experience in the biopharmaceutical industry, contributed to our board of directors’ conclusion that he should serve as a director of our company. ... The audit committee currently consists of Dr. Gray, Mr. Patel and Dr. Sabba (chair). ... Sunil Patel 60,027 94,848 190,025 344,900 ... (5) As of December 31, 2019, Mr. Patel held options to purchase 17,396 shares of our common stock and 835 restricted stock units. During 2019, Mr. Patel received 835 restricted stock units with a grant date fair value of $94,848 and 4,071 stock options with a grant date fair value of $190,025.
2020-11-12	The following table provides information related to the compensation of each of our non-employee directors for fiscal 2019. Sunil Patel Cash Fees $60,027, Stock Awards $94,848, Option Awards $190,025, Total $344,900
2021-04-23	Sunil Patel has served as a member of our board of directors since October 2010. He has more than 20 years of senior management and R&D experience in the biotechnology industry. Mr. Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March 2018. From 2009 to March 2018, Mr. Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals, a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Allos Therapeutics, Connetics, Abgenix and Gilead Sciences. Mr. Patel also worked at McKinsey & Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master’s degree in Molecular Bioengineering/Biotechnology at the University of Washington. Mr. Patel executive and corporate development experience in the biopharmaceutical industry, contributed to our board of directors’ conclusion that he should serve as a director of our company.
2022-04-22	Sunil Patel has served as a member of our board of directors since October 2010. Mr. Patel has senior management and R&D experience in the biotechnology industry. He is a member of the audit committee. Total compensation for 2021 was $322,807.